CAR-T Has A Geography Problem

By Michael Kadan

*This article is originated from PharmaPhorum*

Regulatory approval does not automatically translate to patient accessibility. While advanced cellular immunotherapies offer groundbreaking clinical efficacy, the current delivery model suffers from a significant geographic disconnect. Proximity to specialized treatment hubs remains a primary predictor of whether eligible individuals receive care, overshadowed by logistical constraints rather than biological limitations. The current infrastructure, engineered for small-scale validation, struggles to support broader patient populations due to centralized manufacturing and intricate, multi-step supply chains.

Overcoming these limitations requires shifting focus from basic industrialization to practical operationalization. Designing transferable workflows, standardizing tech transfers, and exploring point-of-care or localized manufacturing are essential steps toward expanding patient reach. Addressing these backend operational bottlenecks early in development ensures that therapeutic innovation becomes universally practical.

Gain comprehensive insights into transforming advanced therapy supply chains and resolving global distribution inequities by exploring the complete breakdown of these operational strategies.